especially VolitionRx given joining that call busy for everyone season. the appreciate you today. earnings call I Thank
excited past saying which our has our been Let how to the become epigenetics always it first see me hope. year, so mainstream over by is start of field extremely
hot at decade team to a and vision this all develop platform, products now together We shows for our accepted come see team. and has the so one incredibly epigenetics scientific have to become epigenetics so even gratifying and been amazing widely a is say time our working when intellectual property, of could
in of with University Nu.Q expand fact our particularly in team innovation work, of grateful on cutting-edge particularly over to owe and and in bringing a is and components the further the happy our made perseverance goal given have recently lung of for have in XX capture in test Vet line. -months, assay colorectal epigenetics all of really three and our Nu.Q most Octamer To members, progress that I acquisition A&M our fronts our that significant your of your and with Texas with say momentum platform cancer capabilities to I'm great development every one program, am house. we the collaboration our past many and fortitude straight
at Firstly and though the given out $XX.X me XXXX. versus XXXX close million this equivalents cash call; in cash of our XXXX with start financials. $XX is million full-year with the let earnings end We
proceeds cash support We year by shareholders. receiving of existing continue throughout exceptional in million the upon to the shareholder enjoy exercise $XX.X warrants
balance towards agencies, governmental to also funding taking funding from non-dilutive our program non-delivery sheets We strengthen our New and million. York further $X.X with date stock various driving total million additional $X.X
remarkably be million approximately work low our We month a of throughout done $X.X all monthly are with to of rate have cash really a to burn proud XXXX. able and consistent
to solid our XXXX manage that carefully to continue cash milestone. with in are key achieve regards runway believe financial position very we We to and a
XXXX into During XXXX, and organization our significantly. grew
Expert in of who assays expanded an has been Assay Our include, instrumental to others, forward. among appointment laboratory team our appreciably taking Validation the
epigenetics last year reagents subsidiaries Veterinary subsidiary, of Diagnostics of We in our early in Octamer operating of formation the the have new of with the also added June XXXX. Volition acquisition part two and
In In connection team through Nu.Q Texas Chief and collaboration Nathan welcomed Executive Schomburg, Medical with Octamer, A&M as with its CEO we Board leading to Officer. of we as the its Volition and Scientific connection founder on Officer the Diagnostics, the the Wilson-Robles our our Vet with to of include Dr. Dewsbury one Veterinary University, of expanded Advisory Nucleosomes experts acquisition Chief Octamer. formation of Dr. Heather world's and Adrian
Phillip Dr. welcomed Board also We our Directors. to of Barnes
first University recently, been first acquisition with Taiwan represents large and memorandums with price that studies understanding and convert a indeed into our part our most of throughout National Vet A&M executed low year, the with this in the Also China. scale Nu.Q have and m XXXX and conduct on in math collaborate relation of of lung cancer expert acquisition. Texas of to company, to recovered University Reagents the which products, to the first delighted the I'm study, development completion early our able nucleus and Octamer, of company's our with we contract to in
thank in for to their hard developing the like the And delighted the executing relationships team I'm all writers with underway. above work work and people these transaction. I'd with on all and
the And improvement have so This completely six led step platforms a outline assay through all so will adapted our to very lab areas. and, key in reproducible, in research, to Nu.Q of asset as has any clinical in shortly. importantly, a change re-engineered development on analytical performance broad they range robust I and that progress, we world. in almost be made can our
this improved performance Clinical carried to performance coming translate We in be into and reported the in out analytical studies month. expect enhanced
access based platforms, a the reproducibility decrease crucial in I'm analytical the the assay to Elisa platforms. a of in of past XX ability below allowing two XX previously X% incredibly assay which to random much XX% commercial format. be automated has turnaround below a Nu.Q hours to to the enables result from one years. The improvement fold of truly of minutes, hour whole program in typical to Relative made range time which the our within the be demonstrate tests. sensitivity magnetic the assay of the assay on results quantitative test throughput, plate is approximately and test six proud XX developed process use recently over format higher and automated for fully effort routine development team developed it wide The particle
XXXX. our studies, during samples these to now We with now chemiluminescence pre close are quarter to assay utilize aim blood these the magnetic analytic and finalizing to clinical automated plasma very reporting assays start in and our excited current throughout data and
and This Octamer processes acquisition our We and this with partners such of expertise developed have of chemiluminescence and as of in by caliburn, house to the antibody Also recent synthetic January this flexibility provides year. nucleosomes continued the brought We speed quantization. magnetic developing areas chain key assay in earlier, or b. have in internalizing nucleosomes now six assets coating as provides up assay for referenced work. create supply to reliable previously specificity, secures our that key development with recombinant which labeling,
based this and throughput. Next assay from assay a to reduces hence sensitivity by time kinetic moving assay and and micro assay format particles format, assay tighter improved plate magnetic increases
further the type format of chemiluminescence greatly background a Moving leading of to from a extending format sensitivity, our assays. improvements magnetic colorimetric assays. a well noise, assay additional traditional range the the to as Akemi specificity reduces of luminescent endpoint with endpoint. usual the as assay in Moreover, greatly endpoint combination This improves
FDA use which currently as improvements automated Finally, approved This and immuno result. assay clinical Europe. in these greatly the and assay United a on an analyzer, is further and moving processing to increases of the across decreases reproducibility time all States reliability
who reduces from any is produced does maybe a same also sample, the the the test to operates when plasma interference. from or where patient serum done, result or correct is blood which So blood regardless And of assay instrument. sample, as test
over the clinical been the working some concept to development, as all-important accuracy clinical performance. of on we past have the XX months, we studies of assess proof terms aforementioned completed assay In have
completed this under finalized cancer assay, is the While curve XX%. at encouraging extremely in essays, the in performance yet lung and development be were ever we even hot a preliminary results cancer area at that to for saw the blood work XX% for
finalized of By C colorectal We our obtain then format beyond. cancers clinical as today, based and hours XXXX, in both of assay range will across the and end assays expect as in the quarter. this cancer, combinations around and believe We're three XXXX the panel finalized have of four to to in assays. the the traditional one data the this of we've excited positive release of performance anticipate second the of the quarter reporting be of of quarter and also to Nu.Q plan four individual by we second to addition product. news Mark useful we plate on Nu.Q further report the In bead end
reactivated study a qualified and under the this, to almost the combining reduces lung XXX we university new amend biomarkers large in approximately the the utilize study. town subjects MTU accrued studies, allowing with regard our of is screening Institute designed gleaned of colorectal X National The glean clinical scale of study. collect trial. validation in collected address recent currently of new gleaned a With XX the our subjects protocol. the the our X,XXX in study, samples national of newly the cancer the aim previously Cancer cohorts with for with targeted to and XX completion previous colorectal cases in samples in available colorectal third collection for is underway is In number cancer. the collected already early cancer decrease colorectal US, detection gleaned incidence study to early agreement well colorectal and X, of of cases new DDRN XX detection the cancer prospectively research agreed to have a collect the design we over To large has the of collected subjects network glean The for studies,
the the tied glean the contributions Our to approval financial which DDRN company's satisfied will previous payments. as company for affect by financial strategy, the study studies, XX use not to studies cancer our already without obligations the product. further for plan been the PMA to X ongoing has studies application still The support fully glean changes to our we screening colorectal should FDA
Belgium, On work the the is in A&M in the are that process side carried an we progress that the now same rapid of we Veterinary with the absolutely I'm help in humans team both delighted Veterinary machines similar, as Officer of the Dr. who Medical same locations. as Chief very so diagnostics, animals Heather can be of use A&M diagnostics. University, as At This knowledge Evolution out the securing absolutely automate making. business, on concurrently and associate is Texas proving today work College our with work animal at the also and Texas will separate and Wilson likely human broaden Veterinary medicine, professor our
we that with believe to Heather is welcome the October year. in last are We A&M formally to signed of thrilled the team. only contract to It hard Texas
And so has already much progress made. been
work out preclinical our get and calendar The conference and to confirmed XXXX. news are prestigious old have a abstracts studies plan two quickly some and throughout is first We busy almost submitted at already a clinical of with presentations number completed conferences underway. the
truly I've the with But way year. as same the this this Volition market. So launch in to Veterinary and said fact market that cetera a for I we opportunity same that formats space. during intellectual believe first given previous little by watch costs, on commercial able it the I we'll we hope Nu.Q products Vet appreciate of utilizes be our calls. our that et additional significant assay, same the this presents very property other creates use
now week, to development epigenetic As this announced novel epigenetics of Nu.Q in new years our have of led earlier many Capture research in multiple the our program. tools
in hopefully diagnostics, only but is to. cancer in other it For areas
these establish position in leadership to lead be by of not technologies potential believe in significant to excited our they epigenetic will more based test. Our a leverage We tools epigenetics. could shift newly blood the that team developed to aim a
areas. nucleosomes and have applications and Nu.Q profiles our for using Nu.Q on cancer patent aim assay based to the our in filed Capture this the of platform with key developed environmental We format several epigenetic base epigenetic in of addition decide tools, novel to
methods and simplify liquid Nu.Q Firstly, cancer nucleosomes biopsies. to sequence enrich Capture based
Capture attack and plasma isolate biomarker the Secondly, to analysis spectrometry discovery both method from Nu.Q diagnostic. mass and in framework our of use nucleosomes clinical
Capture nucleosomes thermal the could prior very circulating This with specific, the concentrate technology Nu.Q and platform Nu.Q multiple is and and tissue measure our methylation to cancer global cancers. our assays a with in Nu.Q format, nuclear And Capture our using detect potential measure be fourthly, exciting. increasing accuracy. simple use finally, of factors, result this Nu.Q a blood therefore by patterns to simple our specific, using markets if transcription in aim to Thirdly, to for test to successful, technology
expand chromosome more investigation circulating broader tools of focus using and fragments status a circulating the potentially that of is on to fragment. diagnostic these epigenetic analysis DNA a developments Volition to powerful patient
ongoing In cancer. base our a of addition format to assay work with in this range
expect data to patient utility abstract, We to well. coming announce be new wide and these and beyond, demonstrating methods months the looking of published papers to forward as posters the and in are
our remarkable quarters. and rates I our their low progress, has to made Overall, with and tireless cash team still burn prior research efforts. development would team thank our entire for keeping consistent like while
intellectual granted aspects that is of patents technology the a growing various On property Volition of protect portfolio front, worldwide steadily. Nu.Q
the other differentiator this with many is market. or the the key believe another under available We technologies in development
granted, Europe eight patents related patent XX in diagnostic our and families worldwide. XX States, XX have a test, We a of United in nine with further to including total
XXX and XX worldwide. including U.S., have we applications XX in patent further pending in the Additionally, Europe, XX
Our the epigenetics our medicine of proprietary future the applications. patent development patents continue apply for [ph] development. product continue work of We Neucleosomics our and to for field will to veterinary also intend covers portfolio through in technology,
and exclusivity patents coverage product, the least market the with products should the Our gain countries. We to believe each in United other including the strategic broad that protection provide and and protect Europe on at our States through strategy is patents underlying XXXX. technology for technologies in
their to recent the Octamer, and components early recombinant transaction other announced supply capability the plans. year at this helps ourselves. nucleosomes our of delighted our to signing And so, close through one Since past January. team accommodated of his strategic Octamer commenced R&D in the acquire reagent the epigenetic just and and now last Schomburg I we're Belgian month, to Munich, key know-how addition already company Adrian December This acquisition quickly to Dr. of cover of we're Nu.Q in test of intention calibrant will very future use the manufacture last with as developing and secure the have We team our the in members in expertise. training and agreement already nucleosomes of
leading that believe goals our further of of this the We work companies. one epigenetic becoming will world's
help third sell to and histones, In we epigenetic the DNA These parties. early drive can custom nucleosomes, and addition for and company. be plan reagents and discovery, to manufacture revenue for applications to in optimas used research templates drug
service samples our of run plan also this later We expand to to service offerings our Belgium with our year. owned
at future, our would so the vision Volition epigenetic science with with to of Looking to like our I our ahead very on what advances epigenetic. founding. focused Nu.Q has since and company the to space. an human reiterate platform in exporting makes our been mission excited us of the it's and fruition And advancing these in the our heart epigenetic come This progress is health.
Volition But expansive extremely significant expanding than team an with work in DNA at us strong is it's DNA to we be epigenetics important of believe our with epigenetic say the if not in last puts not position in short, the in as, is key our IP more full portfolio field. chromosome. player a We this the the decade genetic ever
intend strengthen chain also for key by to in supply components further bringing We health. them our
on hopefully for so progress utility making. and Overall, of delighted We developed the the in immune epigenetics both have final next year. step clinical forward I'm approach field. and growing in half the our our the to assay without look fronts, Nu.Q of team IP with first capture we announcing demonstrating this and ever in excited momentum many And this the by I'm we're sequencing
excited is future who by Our last board, the opportunities. company's our just met including whole team, incredibly scientific week, advisory
animals. be we conference of humans hope to to abstracts, With range key Nu.Q news detect both some in ability release major to year. beyond report aim and position able the and year around conference cash posters regards indeed. several clinical We including this cancers times solid and a Exciting this with papers, to to of our milestones, throughout
other coming look results the In Capture. diagnosis along the world, early delighted improving sharing reputations of all and have and forward addition working our with to of the studies I over collaborators from cancer with our aim be to around year the in We're our rest board, indeed company, the and clinical our platform. Nu.Q optimized whole share absolutely and of the of diseases. key whom to data with outstanding
We happy questions. Operator? to to earnings for expect XXXX now I'm yet. be given very exciting very Thanks I most today. much call year season. appreciated, joining busy the call take the
